Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID.

5 In terms of clinical outcomes, two moderately sized randomized trials published prior to HEART‐FID (Ferric Carboxymaltose in Heart Failure with Iron Deficiency) demonstrated a reduction in HF hospitalizations and cardiovascular deaths in both hospitalized and stable patients which narrowly missed statistical significance. 6 , 7 The HEART‐FID trial further substantiated these results; thus, consideration of iron replacement in eligible patients with HF and ID is warranted. 8 , 9 The efficacy and safety of intravenous ferric carboxymaltose (FCM) has previously been demonstrated in multiple disease states (e.g. chronic kidney disease [CKD], inflammatory bowel disease, heavy uterine bleeding, postpartum period) including HF. 7 , 10 , 11 Prior studies with FCM have shown transient, asymptomatic hypophosphataemia.

also in 86 other papers